Drug resistance mediated by cellular stress response to the microenvironment of solid tumors

Anti-Cancer Drug Design

Volumn 14, Issue 2, 1999, Pages 169-177

  Tomida, Akihiro ^a   Tsuruo, Takashi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Drug resistance; Microenvironment; Solid tumor; Stress response

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLUCOSE; VINCRISTINE;

CANCER CELL; CELL CYCLE G1 PHASE; CELL DIVISION; CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STRESS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033043841     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proceedings of the National Academy of Sciences, USA, 84, 5565.
2. Beck W.T., Danks M.K., Wolverton J.S., Chen M., Granzen B., Kim R., Suttle D.P. (1994) Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Advances in Pharmacology, 29B, 145.
3. Boehm T., Folkman J., Browder T., O'Reilly M.S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404.
4. Bosl G.J., Bajorin D.F. (1994) Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison. Seminars in Oncology, 21, 61.
5. Brown J.M., Giaccia A.J. (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Research, 58, 1408.
6. Cai J.W., Henderson B.W., Shen J.W., Subjeck J.R. (1993) Induction of glucose regulated proteins during growth of a murine tumor. Journal of Cellular Physiology, 154, 229.
7. Cai B., Tomida A., Mikami K., Nagata K., Tsuruo T. (1998) Down-regulation of epidermal growth factor receptor-signaling pathway by binding of GRP78/BiP to the receptor under glucose-starved stress conditions. Journal of Cellular Physiology, 177, 282.
8. Capranico G., Binaschi M., Borgnetto M.E., Zunino F., Palumbo M. (1997) A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends in Pharmacological Sciences, 18, 323.
9. Chang J.Y., Dethlefsen L.A., Barley L.R., Zhou B.S., Cheng Y.C. (1992) Characterization of camptothecin-resistant Chinese hamster lung cells. Biochemical Pharmacology, 43, 2443.
10. Chatterjee S., Cheng M.F., Berger R.B., Berger S.J., Berger N.A. (1995) Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide. Cancer Research, 55, 868.
11. Chatterjee S., Hirota H., Belfi C.A., Berger S.J., Berger N.A. (1997) Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78. Cancer Research, 57, 5112.
12. Chen A.Y., Liu L.F. (1994a) DNA topoisomerases: essential enzymes and lethal targets. Annual Review of Pharmacology and Toxicology, 34, 191.
13. Chen A.Y., Liu L.F. (1994b) Mechanisms of resistance to topoisomerase inhibitors. Cancer Treatment and Research, 73, 263.
14. Chow K.C., Ross W.E. (1987) Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Molecular and Cellular Biology, 7, 3119.
15. Dorner A.J., Bole D.G., Kaufman R.J. (1987) The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. Journal of Cell Biology, 105, 2665.
16. Dorner A.J., Kaufman R.J. (1994) The levels of endoplasmic reticulum proteins and ATP affect folding and secretion of selective proteins. Biologicals, 22, 103.
17. Dorner A.J., Krane M.G., Kaufman R.J. (1988) Reduction of endogenous GRP78 levels improves secretion of a heterologous protein in CHO cells. Molecular and Cellular Biolology, 8, 4063.
18. Dorner A.J., Wasley L.C., Kaufman R.J. (1992) Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO Journal, 11, 1563.
19. Doyle L.A. (1994) Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemotherapy and Pharmacology, 34, S32.
20. Forastiere A.A. (1994) Overview of platinum chemotherapy in head and neck cancer. Seminars in Oncology, 21, 20.
21. Froelich-Ammon S.J., Osheroff N. (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. Journal of Biological Chemistry, 270, 21429.
22. Gething M.-J., Sambrook J. (1992) Protein folding in the cell. Nature, 355, 33.
23. Gething M.-J., Blond-Elguindi S., Mori K., Sambrook J. (1994) Structure, function, and regulation of the endoplasmic reticulum chaperone, BiP. In The Biology of Heat Shock Proteins and Molecular Chaperones. Morimoto I.R., Tissieres A., Georgopoulos C. (eds), p. 111. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.
24. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proceedings of the National Academy of Sciences, USA, 89, 3070.
25. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Molecular and Cellular Biology, 14, 6264.
26. Grana X., Reddy E.P. (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs) Oncogene, 11, 211.
27. Green S.L., Giaccia A.J. (1998) Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer Journal from Scientific American, 4, 218.
28. Gupta R.S., Gupta R., Eng B., Lock R.B., Ross W.E., Hertzberg R.P., Caranfa M.J., Johnson R.K. (1988) Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Research, 48, 6404.
29. Heck M.M., Earnshaw W.C. (1986) Topoisomerase II: a specific marker for cell proliferation. Journal of Cell Biology, 103, 2569.
30. Heck M.M., Hittelman W.N., Earnshaw W.C. (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proceedings of the National Academy of Sciences, USA, 85, 1086.
31. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research, 56, 4509.
32. Hsiang Y.H., Wu H.Y., Liu L.F. (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Research, 48, 3230.
33. Hughes C.S., Shen J.W., Subjeck J.R. (1989) Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Research, 49, 4452.
34. Hunter T., Pines J. (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 79, 573.
35. Jamora C., Dennert G., Lee A.S. (1996) Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proceedings of the National Academy of Sciences, USA, 93, 7690.
36. Johnson S.W., Swiggard P.A., Handel L.M., Brennan J.M., Godwin A.K., Ozols R.F., Hamilton T.C. (1994) Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Research, 54, 5911.
37. Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K., Fujiwara Y., Liu L.F., Saijo N. (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Research, 50, 5919.
38. Kaufmann W.K., Paules R.S. (1996) DNA damage and cell cycle checkpoints. FASEB Journal, 10, 238.
39. Kelley S.L., Basu A., Teicher B.A., Hacker M.P., Hamer D.H., Lazo J.S. (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241, 1813.
40. Kerbel R.S., Viloria-Petit A., Okada F., Rak J. (1998) Establishing a link between oncogenes and tumor angiogenesis. Molecular Medicine, 4, 286.
41. Kimura H., Braun R.D., Ong E.T., Hsu R., Secomb T.W., Papahadjopoulos D., Hong K., Dewhirst M.W. (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Research, 56, 5522.
42. Lai G-M., Ozols R.F., Smyth J.F., Young R.C., Hamilton T.C. (1988) Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochemical Pharmacology, 37, 4597.
43. Lee A.S. (1981) The accumulation of three specific proteins related to glucose-regulated proteins in a temperature-sensitive hamster mutant cell line K12. Journal of Cellular Physiology, 106, 119.
44. Lee A.S. (1987) Coordinated regulation of a set of genes by glucose and calcium ionophores in mammalian cells. Trends in Biochemical Sciences, 12, 20.
45. Lee A.S. (1992) Mammalian stress response: induction of the glucose-regulated protein family. Current Opinion in Cell Biology, 4, 267.
46. Liu L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry, 58, 351.
47. Lohrer H.D. (1996) Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Experientia, 52, 316.
48. Malonne H., Atassi G. (1997) DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs, 8, 811.
49. 1 phase of the cell cycle. Cell, 65, 701.
50. Mayes E.L., Waterfield M.D. (1984) Biosynthesis of the epidermal growth factor receptor in A431 cells. EMBO Journal, 3, 531.
51. Melero J.A. (1981) Identification of the glucose/glycosylation-regulated proteins as those which accumulate in the temperature-sensitive cell line K12. Journal of Cellular Physiology, 109, 59.
52. Morgan D.O. (1995) Principles of CDK regulation. Nature, 374, 131.
53. Moulder J.E., Rockwell S. (1987) Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Reviews, 5, 313.
54. Nelson W.G., Cho K.R., Hsiang Y.H., Liu L.F., Coffey D.S. (1987) Growth-related elevations of DNA topoisomerase II levels found in Dunning R3327 rat prostatic adenocarcinomas. Cancer Research, 47, 3246.
55. Oldenburg J., Begg A.C., van Vugt M.J.H., Ruevekamp M., Schornagel J.H., Pinedo H.M., Los, G. (1994) Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 adenocarcinoma cell line in vitro. Cancer Research, 54, 487.
56. Olson T.S., Lane M.D. (1989) A common mechanism for posttranslational activation of plasma membrane receptors? FASEB Journal, 3, 1618.
57. Ozols R.F. (1992) New developments with carboplatin in the treatment of ovarian cancer. Seminars in Oncology, 19, 85.
58. Parker R.J., Eastman A., Bosstick-Bruton F., Reed E. (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. Journal of Clinical Investigation, 87, 772.
59. Pommier Y., Leteurtre F., Fesen M.R., Fujimori A., Bertrand R., Solary E., Kohlhagen G., Kohn K.W. (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investigation, 12, 530.
60. Reedijk J. (1987) The mechanism of action of platinum anti-tumor drugs. Pure and Applied Chemistry, 59, 181.
61. Rockwell S., Moulder J.E. (1990) Hypoxic fractions of human tumors xenografted into mice: a review. International Journal of Radiation Oncology Biology and Physics, 19, 197.
62. Schmaltz C., Hardenbergh P.H., Wells A., Fisher D.E. (1998) Regulation of proliferation-survival decisions during tumor cell hypoxia. Molecular and Cellular Biology, 18, 2845.
63. Shen J., Hughes C., Chao C., Cai J., Bartels C., Gessner T., Subjeck J. (1987) Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proceedings of the National Academy of Sciences, USA, 84, 3278.
64. Shen J.W., Subjeck J.R., Lock R.B., Ross W.E. (1989) Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response. Molecular and Cellular Biology, 9, 3284.
65. 1 phase progression: cycling on cue. Cell, 79, 551.
66. Sidrauski C., Chapman R., Walter P. (1998) The unfolded protein response: an intracellular signalling pathway with many surprising features. Trends in Cell Biology, 8, 245.
67. Slieker L.J., Martensen T.M., Lane M.D. (1986) Synthesis of epidermal growth factor receptor in human A431 cells. Glycosylation-dependent acquisition of ligand binding activity occurs post-translationally in the endoplasmic reticulum. Journal of Biological Chemistry, 261, 15233.
68. Soderquist A.M., Carpenter G. (1984) Glycosylation of the epidermal growth factor receptor in A-431 cells. The contribution of carbohydrate to receptor function. Journal of Biological Chemistry, 259, 12586.
69. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Research, 50, 6925.
70. Sullivan D.M., Latham M.D., Ross W.E. (1987) Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Research, 47, 3973.
71. Sutherland R.M. (1988) Cell and environment interactions in tumor microregions: the multicell spheroid model. Science, 240, 177.
72. Takeda S., Shimazoe T., Sato K., Sugimoto Y., Tsuruo T., Kono A. (1992) Differential expression of DNA topoisomerase I gene between CPT-11 acquired-and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay. Biochemical and Biophysical Research Communications, 184, 618.
73. Teicher B.A. (1994) Hypoxia and drug resistance. Cancer Metastasis Reviews, 13, 139.
74. Tenner A., Zieg J., Scheffler I.E. (1977) Glycoprotein synthesis in a temperature-sensitive Chinese hamster cell cycle mutant. Journal of Cellular Physiology, 90, 145.
75. Tirasophon W., Welihinda A.A., Kaufman R.J. (1998) A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/ endoribonuclease (Ire1p) in mammalian cells. Genes and Development, 12, 1812.
76. Tomida A., Suzuki H., Kim H.-D., Tsuruo T. (1996a) Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene, 13, 2699.
77. Tomida A., Yun J., Tsuruo T. (1996b) Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. International Journal of Cancer, 68, 391.
78. Vaupel P.W. (1993) Oxygenation of solid tumors. In Drug Resistance in Oncology. Teicher B.A. (ed.), p. 53. Marcel Dekker: New York.
79. Vaupel P., Kallinowski F., Okunieff P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Research, 49, 6449.
80. Wang J.C. (1996) DNA topoisomerases. Annual Review of Biochemistry, 65, 635.
81. Wang X.-Z., Harding P.H., Zhang Y., Kuroda M., Ron D. (1998) Cloning of mammalian Ire1 reveals diversity in the ER stress responses. EMBO Journal, 17, 5708.
82. Wike-Hooley J.L., Haveman J., Reinhold H.S. (1984) The relevance of tumour pH to the treatment of malignant disease. Radiotherapy and Oncology, 2, 343.
83. Yamada M., Tomida A., Yun J., Cai B., Yoshikawa H., Taketani Y., Tsuruo T. (1999) Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemotherapy and Pharmacology, in press.
84. Yun J., Tomida A., Nagata K., Tsuruo T. (1995) Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncology Research, 7, 583.